Aliases & Classifications for Personality Disorder

MalaCards integrated aliases for Personality Disorder:

Name: Personality Disorder 12 29 14
Personality Disorders 52 41 69
Character Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1510
ICD9CM 35 301.8 301.89
ICD10 33 F60 F60.9
UMLS 69 C0029707

Summaries for Personality Disorder

MedlinePlus : 41 personality disorders are a group of mental illnesses. they involve long-term patterns of thoughts and behaviors that are unhealthy and inflexible. the behaviors cause serious problems with relationships and work. people with personality disorders have trouble dealing with everyday stresses and problems. they often have stormy relationships with other people. the cause of personality disorders is unknown. however, genes and childhood experiences may play a role. the symptoms of each personality disorder are different. they can mild or severe. people with personality disorders may have trouble realizing that they have a problem. to them, their thoughts are normal, and they often blame others for their problems. they may try to get help because of their problems with relationships and work. treatment usually includes talk therapy and sometimes medicine.

MalaCards based summary : Personality Disorder, also known as personality disorders, is related to paranoid personality disorder and multiple personality disorder, and has symptoms including fatigue, sleep disturbances and photophobia. An important gene associated with Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Fluvoxamine and Topiramate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Disease Ontology : 12 A disease of mental health that involve long-term patterns of thoughts and behaviors that cause serious problems with relationships and work.

Wikipedia : 72 Personality disorders (PD) are a class of mental disorders characterized by enduring maladaptive... more...

Related Diseases for Personality Disorder

Diseases in the Personality Disorder family:

Multiple Personality Disorder

Diseases related to Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 185)
id Related Disease Score Top Affiliating Genes
1 paranoid personality disorder 34.2 HTR1A HTR2A
2 multiple personality disorder 32.9 DRD4 MAOA MAOB
3 antisocial personality disorder 32.6 ANKK1 DRD2 DRD3 DRD4
4 obsessive-compulsive personality disorder 32.1 COMT HTR1A HTR1B HTR2A HTR2C MAOA
5 dissociative disorder 30.0 DRD3 SLC6A4
6 asperger syndrome 29.2 DRD2 DRD3 SLC6A3
7 heroin dependence 27.9 DRD2 DRD3 DRD4 HTR1B MAOA SLC6A3
8 schizophrenia 24.6 COMT DRD2 DRD3 DRD4 HTR1A HTR1B
9 borderline personality disorder 12.4
10 avoidant personality disorder 12.4
11 dependent personality disorder 12.3
12 histrionic personality disorder 12.3
13 schizoid personality disorder 12.3
14 schizotypal personality disorder 12.3
15 narcissistic personality disorder 12.2
16 intermittent explosive disorder 11.4
17 cyclothymic disorder 10.8
18 conduct disorder 10.8
19 sexual sadism 10.7
20 ring chromosome 14 syndrome 10.5 COMT MAOA
21 angiokeratoma of mibelli 10.5 HTR1A MAOA SLC6A4
22 ornithosis 10.5 DRD2 MAOA SLC6A4
23 impulse control disorder 10.5
24 polyneuropathy 10.4 HTR1A HTR2A
25 neurogenic bladder 10.4 HTR2A MAOA SLC6A4
26 hodgkin's granuloma 10.4 HTR1A HTR2A
27 intracranial cavernous angioma 10.4 DRD2 SLC6A3 SLC6A4
28 chitty hall webb syndrome 10.4 COMT TPH1
29 rhinoscleroma 10.4 COMT DRD2
30 myopathy, distal, with early respiratory failure, autosomal dominant 10.4 COMT SLC6A3 TPH1
31 hyperthyroxinemia 10.3 DRD2 HTR2A SLC6A4
32 uterus intravascular leiomyomatosis 10.3 COMT HTR1A MAOA SLC6A4
33 chronic dacryoadenitis 10.3 COMT HTR1A MAOA SLC6A4
34 velocardiofacial syndrome 10.3
35 dissociative seizures 10.3
36 gardner-diamond syndrome 10.3
37 ceroid lipofuscinosis, neuronal, 7 10.3
38 dystonia-11, myoclonic 10.3
39 ceroid lipofuscinosis, neuronal, 8 10.3
40 bladder hepatoid adenocarcinoma 10.3 DRD2 SLC6A3 SLC6A4
41 allergic hypersensitivity disease 10.2 DRD2 HTR1A HTR2A
42 chromosome 11p13 deletion syndrome, distal 10.2 COMT HTR2A SLC6A4
43 vascular cancer 10.2 DRD2 HTR1A HTR2A
44 pelvic inflammatory disease 10.2 DRD2 HTR2C SLC6A4
45 tinea pedis 10.2 HTR1A MAOA SLC6A3 SLC6A4
46 social phobia 10.2
47 c8 deficiency, type ii 10.1 COMT DRD2 DRD4
48 obsessive-compulsive disorder 10.1
49 anxiety disorder 10.1
50 substance dependence 10.1

Comorbidity relations with Personality Disorder via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Alzheimer Disease
Anxiety Disorder Deficiency Anemia
Dependent Personality Disorder Dysthymic Disorder
Generalized Anxiety Disorder Heart Disease
Hypertension, Essential Hypothyroidism
Parkinson Disease, Late-Onset Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Personality Disorder:



Diseases related to Personality Disorder

Symptoms & Phenotypes for Personality Disorder

UMLS symptoms related to Personality Disorder:


fatigue, sleep disturbances, photophobia, personality changes, restlessness, pseudobulbar behavioral symptoms

GenomeRNAi Phenotypes related to Personality Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.32 ALDH2 ANKK1 COMT DRD2 DRD3 DRD4

MGI Mouse Phenotypes related to Personality Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.24 TPH1 TPH2 ALDH2 COMT DRD2 DRD3
2 homeostasis/metabolism MP:0005376 10.07 ALDH2 COMT DRD2 DRD3 DRD4 HTR1A
3 cardiovascular system MP:0005385 9.97 DRD3 HTR1A HTR1B MAOA SLC6A4 TPH1
4 adipose tissue MP:0005375 9.8 DRD2 DRD3 HTR2C TPH1 TPH2
5 integument MP:0010771 9.7 ALDH2 DRD2 HTR2C SLC6A3 SLC6A4 TPH1
6 muscle MP:0005369 9.5 DRD2 HTR1B HTR2A HTR2C SLC6A3 SLC6A4
7 nervous system MP:0003631 9.4 ALDH2 COMT DRD2 DRD3 DRD4 HTR1A

Drugs & Therapeutics for Personality Disorder

Drugs for Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluvoxamine Approved, Investigational Phase 4,Phase 3 54739-18-3 3404 5324346
2
Topiramate Approved Phase 4,Phase 3 97240-79-4 5284627
3
Citalopram Approved Phase 4,Phase 3,Phase 2 59729-33-8 2771
4
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
5
Risperidone Approved, Investigational Phase 4,Phase 1,Phase 2 106266-06-2 5073
6
Cycloserine Approved Phase 4,Phase 3,Phase 2 68-41-7 401 6234
7
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3 113-45-1 4158
8
Clomipramine Approved, Vet_approved Phase 4,Phase 3,Phase 2 303-49-1 2801
9
Ethanol Approved Phase 4,Phase 2,Phase 3 64-17-5 702
10
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
11
Lamotrigine Approved, Investigational Phase 4,Phase 2 84057-84-1 3878
12
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2 54910-89-3 3386
13
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
14
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
15
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
16
Haloperidol Approved Phase 4 52-86-8 3559
17
Norepinephrine Approved Phase 4,Phase 3,Phase 2 51-41-2 439260
18
Sertraline Approved Phase 4,Phase 3,Phase 2,Phase 1 79617-96-2 68617
19
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
20
Propranolol Approved, Investigational Phase 4 525-66-6 4946
21
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
22
Naratriptan Approved, Investigational Phase 4 143388-64-1, 121679-13-8 4440
23
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
24
Maleic acid Experimental Phase 4,Phase 3 110-16-7 444266
25 Anti-Anxiety Agents Phase 4,Phase 3,Phase 1,Phase 2
26 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2,Phase 1
28 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
29 Cytochrome P-450 CYP1A2 Inhibitors Phase 4,Phase 3
30 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2
33 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
34
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
35 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2
37 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Anticonvulsants Phase 4,Phase 3,Phase 2
39 Anti-Obesity Agents Phase 4,Phase 3
40 Neuroprotective Agents Phase 4,Phase 3,Phase 2
41 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Cholinergic Agents Phase 4,Phase 3,Phase 2
45 Cholinergic Antagonists Phase 4,Phase 3,Phase 2
46 Muscarinic Antagonists Phase 4,Phase 3,Phase 2
47 Parasympatholytics Phase 4,Phase 3,Phase 2
48 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 588)

id Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD) Unknown status NCT00743834 Phase 4 Luvox CR
3 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Unknown status NCT00211744 Phase 4 topiramate
4 Treatment Youth With Obsessive-Compulsive Disorder Unknown status NCT00708240 Phase 4 Escitalopram
5 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
6 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
7 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
8 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4 risperidone
9 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
10 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
11 Augmentation in Tx-resistant OCD: an Open Label Trial Completed NCT00590642 Phase 4
12 D-Cycloserine as an Adjunct to Internet-CBT for OCD Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
13 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
14 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
15 Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD) Completed NCT00796497 Phase 4 ondansetron
16 Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00116532 Phase 4 Escitalopram
17 Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
18 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
19 Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD) Completed NCT00464698 Phase 4 Duloxetine
20 Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-Compulsive Disorder Patients Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
21 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed NCT00466609 Phase 4 clomipramine and fluoxetine;quetiapine and fluoxetine;placebo and fluoxetine
22 Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF) Completed NCT01135745 Phase 4
23 Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
24 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
25 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder Completed NCT00723060 Phase 4 escitalopram
26 Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA) Completed NCT00000388 Phase 4 Anti-ADHD medication
27 Antidepressant Safety in Kids Study Completed NCT00395213 Phase 4 Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications
28 Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
29 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
30 Treatments for Psychogenic Nonepileptic Seizures (NES) Completed NCT00159965 Phase 4 sertraline;placebo
31 Treatment Trial for Psychogenic Nonepileptic Seizures Completed NCT00835627 Phase 4 sertraline
32 Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline. Recruiting NCT03068429 Phase 4 Sertraline Hydrochloride
33 Brief Intervention for OCD Fears Recruiting NCT02790710 Phase 4 Propanolol;Placebo
34 Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD) Recruiting NCT00182520 Phase 4 Topiramate;placebo
35 Probiotic Treatment in Adult Obsessive-Compulsive Disorder Recruiting NCT02334644 Phase 4
36 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Recruiting NCT00994786 Phase 4 pregabalin;Placebo
37 Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients Recruiting NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
38 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
39 Attaining and Maintaining Wellness in Obsessive-compulsive Disorder Active, not recruiting NCT01686087 Phase 4
40 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? Active, not recruiting NCT02656342 Phase 4 D-Cycloserine;Placebo
41 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Active, not recruiting NCT00182533 Phase 4 Sertraline;Placebo
42 Pharmacology of Cognition in Schizotypal Personality Disorder Terminated NCT00353379 Phase 4 Guanfacine;Placebo
43 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
44 Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
45 Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
46 Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain Withdrawn NCT00227292 Phase 4 Escitalopram;Placebo
47 BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder Completed NCT00538135 Phase 3
48 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
49 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
50 Olanzapine in Patients With Borderline Personality Disorder Completed NCT00091650 Phase 3 Olanzapine;placebo

Search NIH Clinical Center for Personality Disorder

Genetic Tests for Personality Disorder

Genetic tests related to Personality Disorder:

id Genetic test Affiliating Genes
1 Personality Disorder 29

Anatomical Context for Personality Disorder

MalaCards organs/tissues related to Personality Disorder:

39
Brain, Testes, Cortex, Heart, Prefrontal Cortex, Liver, Amygdala

Publications for Personality Disorder

Articles related to Personality Disorder:

(show top 50) (show all 2109)
id Title Authors Year
1
Reduced white matter integrity in borderline personality disorder: A diffusion tensor imaging study. ( 28922736 )
2018
2
People with Borderline Personality Disorder and Burns: Some Considerations for Health Professionals. ( 28945490 )
2017
3
Face and gaze perception in borderline personality disorder: An electrical neuroimaging study. ( 28941875 )
2017
4
Orbito-frontal cortex volumes in patients with antisocial personality disorder. ( 28784365 )
2017
5
Using online, crowdsourcing platforms for data collection in personality disorder research: The example of Amazon's Mechanical Turk. ( 28045305 )
2017
6
Reduced functional connectivity between bilateral precuneus and contralateral parahippocampus in schizotypal personality disorder. ( 28152990 )
2017
7
Borderline personality disorder and polycystic ovary syndrome: A review of the literature. ( 28891300 )
2017
8
Resting cardiac function in adolescent non-suicidal self-injury: The impact of borderline personality disorder symptoms and psychosocial functioning. ( 28039803 )
2017
9
Estimating the prevalence of borderline personality disorder in mothers involved in youth protection services. ( 28944592 )
2017
10
Intersect between self-esteem and emotion regulation in narcissistic personality disorder - implications for alliance building and treatment. ( 28191317 )
2017
11
Helping mothers with the emotional dysregulation of borderline personality disorder and their infants in primary care settings. ( 28892598 )
2017
12
Impact of obsessive-compulsive personality disorder symptoms in Internet users. ( 28738097 )
2017
13
A Mother's Borderline Personality Disorder and Her Sensitivity, Autonomy Support, Hostility, Fearful/Disoriented Behavior, and Role Reversal With Her Young Child. ( 28072039 )
2017
14
Efficacy of metacognitive training for patients with borderline personality disorder: Preliminary results. ( 28927866 )
2017
15
Determining if Borderline Personality Disorder and Bipolar Disorder Are Alternative Expressions of the Same Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. ( 28922592 )
2017
16
Comparing Facial Emotional Recognition in Patients with Borderline Personality Disorder and Patients with Schizotypal Personality Disorder with a Normal Group. ( 28659980 )
2017
17
Predictive Utility of Personality Disorder in Depression: Comparison of Outcomes and Taxonomic Approach. ( 28926307 )
2017
18
Did you get any help? A post-hoc secondary analysis of a randomized controlled trial of psychoeducation for patients with antisocial personality disorder in outpatient substance abuse treatment programs. ( 28068951 )
2017
19
Associations of borderline personality disorder traits with stressful events and emotional reactivity in women with bulimia nervosa. ( 28691843 )
2017
20
Oxytocin improves facial emotion recognition in young adults with antisocial personality disorder. ( 28865940 )
2017
21
PDTRT Special Section: Methodological issues in personality disorder research. ( 28045301 )
2017
22
Combined Oral Contraceptive Pill Initiation in a Patient With Major Depressive Disorder, Premenstrual Dysphoric Disorder, Social Anxiety, Panic Disorder, and Histrionic Personality Disorder. ( 28638292 )
2017
23
Personality disorders in cluster headache: a study using the Millon Clinical Multiaxial Inventory-III. ( 28527059 )
2017
24
The Relationship between Survival Sex and Borderline Personality Disorder Symptoms in a High Risk Female Population. ( 28885558 )
2017
25
Countertransference when working with narcissistic personality disorder: An empirical investigation. ( 28581327 )
2017
26
Outcome Trajectories and Prognostic Factors for Suicide and Self-Harm Behaviors in Patients With Borderline Personality Disorder Following One Year of Outpatient Psychotherapy. ( 28910214 )
2017
27
Treatment outcomes for inpatients with obsessive-compulsive personality disorder: An open comparison trial. ( 27988411 )
2017
28
Stability or instability in avoidant personality disorder:Mode fluctuations within schema therapy sessions. ( 28527713 )
2017
29
The current state and future of factor analysis in personality disorder research. ( 28045304 )
2017
30
Substance Misuse Is Associated With Increased Psychiatric Severity Among Treatment-Seeking Individuals With Borderline Personality Disorder. ( 28910215 )
2017
31
Substance and Evaluation in Personality Disorder Diagnoses. ( 28910217 )
2017
32
Genetic and Environmental Structure of DSM-IV Criteria for Antisocial Personality Disorder: A Twin Study. ( 28108863 )
2017
33
Subgroups of Adolescent Girls With Borderline Personality Disorder Symptoms. ( 28926303 )
2017
34
Change of Unresolved Attachment in Borderline Personality Disorder: RCT Study of Transference-Focused Psychotherapy. ( 28903103 )
2017
35
Insomnia in adult attention-deficit/hyperactivity disorder: A comparison with borderline personality disorder population in a clinical setting and control participants. ( 28501733 )
2017
36
Attachment Style and Resiliency in Patients with Obsessive-Compulsive Personality Disorder. ( 28197331 )
2017
37
"Abandonment Psychotherapy" for Suicidal Patients with Borderline Personality Disorder: Long-Term Outcome. ( 28903102 )
2017
38
Interpersonal Threat Sensitivity in Borderline Personality Disorder: An Eye-Tracking Study. ( 28072041 )
2017
39
Neural Mechanisms Underlying Affective Theory of Mind in Violent Antisocial Personality Disorder and/or Schizophrenia. ( 28199713 )
2017
40
Clinical Characteristics of Comorbid Narcissistic Personality Disorder in Patients With Borderline Personality Disorder. ( 28758884 )
2017
41
Contrasting metacognitive, social cognitive and alexithymia profiles in adults with borderline personality disorder, schizophrenia and substance use disorder. ( 28826064 )
2017
42
Reduced White Matter Integrity in Antisocial Personality Disorder: A Diffusion Tensor Imaging Study. ( 28223713 )
2017
43
Gene expression study of mitochondrial complex I in schizophrenia and paranoid personality disorder. ( 28635542 )
2017
44
Using personality neuroscience to study personality disorder. ( 28045302 )
2017
45
More inflammation but less brain-derived neurotrophic factor in antisocial personality disorder. ( 28810156 )
2017
46
Personality organization and its association with clinical and functional features in borderline personality disorder. ( 28923434 )
2017
47
Substance Use in Youth With Borderline Personality Disorder. ( 28926304 )
2017
48
Predicting Nonsuicidal Self-Injury in Borderline Personality Disorder Using Ecological Momentary Assessment. ( 28072044 )
2017
49
Pain Perception and Body Awareness Among Individuals With Borderline Personality Disorder. ( 28902571 )
2017
50
Personality disorders and pathological gambling. ( 27798487 )
2017

Variations for Personality Disorder

Expression for Personality Disorder

Search GEO for disease gene expression data for Personality Disorder.

Pathways for Personality Disorder

Pathways related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.43 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A
2
Show member pathways
12.86 ALDH2 COMT MAOA SLC6A3 SLC6A4
3
Show member pathways
12.64 COMT DRD2 DRD3 DRD4 MAOA MAOB
4 12.4 COMT HTR1A TPH1 TPH2
6
Show member pathways
12.12 ALDH2 MAOA MAOB TPH1 TPH2
7 12.06 HTR1A HTR2A MAOA SLC6A4 TPH1 TPH2
8
Show member pathways
11.91 DRD2 MAOA MAOB SLC6A3
9 11.77 DRD3 DRD4 HTR2A
10
Show member pathways
11.76 DRD2 DRD3 DRD4
11
Show member pathways
11.76 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A
12 11.66 HTR1A HTR1B HTR2A HTR2C MAOA MAOB
13
Show member pathways
11.62 COMT MAOA MAOB
14
Show member pathways
11.49 ALDH2 MAOA MAOB
15
Show member pathways
11.39 MAOA SLC6A3 SLC6A4 TPH2
16
Show member pathways
11.27 ALDH2 MAOA MAOB
17
Show member pathways
11.09 ALDH2 COMT MAOA SLC6A3 SLC6A4
18
Show member pathways
11.04 COMT MAOA TPH1
19 11.01 DRD2 DRD3
20 10.9 HTR2A HTR2C
21 10.83 COMT MAOA MAOB
22
Show member pathways
10.78 ALDH2 MAOA MAOB
23
Show member pathways
10.77 ALDH2 COMT MAOA MAOB
24 10.67 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4

GO Terms for Personality Disorder

Cellular components related to Personality Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.73 COMT DRD2 DRD3 DRD4 HTR1A HTR1B
2 neuron projection GO:0043005 9.56 SLC6A3 SLC6A4 TPH1 TPH2
3 axon GO:0030424 9.46 COMT DRD2 HTR2A SLC6A3
4 integral component of plasma membrane GO:0005887 9.28 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A

Biological processes related to Personality Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
id Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 9.91 DRD3 DRD4 HTR2A HTR2C
2 response to toxic substance GO:0009636 9.9 DRD2 MAOB SLC6A4
3 locomotory behavior GO:0007626 9.9 DRD2 DRD3 HTR2C SLC6A3
4 circadian rhythm GO:0007623 9.88 SLC6A4 TPH1 TPH2
5 positive regulation of fat cell differentiation GO:0045600 9.86 HTR2A HTR2C TPH1
6 social behavior GO:0035176 9.85 DRD3 DRD4 SLC6A4
7 feeding behavior GO:0007631 9.85 DRD2 HTR1B HTR2C
8 response to ethanol GO:0045471 9.85 DRD2 DRD3 HTR1B MAOB SLC6A3
9 release of sequestered calcium ion into cytosol GO:0051209 9.83 DRD2 HTR2A HTR2C
10 negative regulation of adenylate cyclase activity GO:0007194 9.81 DRD2 DRD3 DRD4
11 behavioral fear response GO:0001662 9.81 DRD4 HTR1A HTR2C
12 response to amphetamine GO:0001975 9.79 DRD2 DRD3 DRD4
13 arachidonic acid secretion GO:0050482 9.79 DRD2 DRD3 DRD4
14 response to cocaine GO:0042220 9.78 DRD2 DRD3 HTR1B SLC6A3
15 dopamine receptor signaling pathway GO:0007212 9.77 DRD2 DRD3 DRD4
16 vasoconstriction GO:0042310 9.76 HTR1A HTR1B SLC6A4
17 negative regulation of protein secretion GO:0050709 9.75 DRD2 DRD3 DRD4
18 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.74 DRD2 HTR1B HTR2A
19 temperature homeostasis GO:0001659 9.73 DRD2 HTR2A
20 response to iron ion GO:0010039 9.73 DRD2 SLC6A3
21 synaptic transmission, dopaminergic GO:0001963 9.73 DRD2 DRD3
22 negative regulation of cAMP biosynthetic process GO:0030818 9.73 DRD4 HTR1B
23 prepulse inhibition GO:0060134 9.73 DRD2 DRD3 SLC6A3
24 behavioral response to ethanol GO:0048149 9.72 DRD2 DRD4
25 positive regulation of kinase activity GO:0033674 9.72 DRD4 HTR2A
26 bone remodeling GO:0046849 9.72 HTR1B TPH1
27 neurotransmitter biosynthetic process GO:0042136 9.72 SLC6A3 SLC6A4
28 G-protein coupled receptor internalization GO:0002031 9.72 DRD2 DRD3 HTR1B
29 negative regulation of voltage-gated calcium channel activity GO:1901386 9.71 DRD2 DRD4
30 ammonium transmembrane transport GO:0072488 9.71 SLC6A3 SLC6A4
31 positive regulation of renal sodium excretion GO:0035815 9.71 DRD2 DRD3
32 catecholamine metabolic process GO:0006584 9.71 COMT MAOA
33 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.71 DRD2 DRD3 DRD4
34 regulation of dopamine secretion GO:0014059 9.71 DRD2 DRD3 HTR1B HTR2A
35 adenohypophysis development GO:0021984 9.7 DRD2 SLC6A3
36 monoamine transport GO:0015844 9.7 SLC6A3 SLC6A4
37 aromatic amino acid family metabolic process GO:0009072 9.7 TPH1 TPH2
38 dopamine uptake involved in synaptic transmission GO:0051583 9.7 SLC6A3 SLC6A4
39 neurotransmitter catabolic process GO:0042135 9.7 COMT MAOA MAOB
40 regulation of cAMP metabolic process GO:0030814 9.69 DRD2 DRD3
41 regulation of hormone secretion GO:0046883 9.69 HTR1A HTR2A
42 indolalkylamine biosynthetic process GO:0046219 9.69 TPH1 TPH2
43 regulation of dopamine metabolic process GO:0042053 9.69 DRD4 HTR1A SLC6A3
44 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.68 DRD2 DRD3
45 negative regulation of serotonin secretion GO:0014063 9.67 HTR1B MAOB
46 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.67 HTR1A HTR1B
47 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.67 HTR2A HTR2C
48 regulation of behavior GO:0050795 9.67 HTR1A HTR1B HTR2A
49 behavioral response to cocaine GO:0048148 9.67 DRD2 DRD3 DRD4 HTR2A
50 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.65 DRD2 DRD4

Molecular functions related to Personality Disorder according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.96 ALDH2 MAOA MAOB TPH1 TPH2
2 signal transducer activity GO:0004871 9.91 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A
3 neurotransmitter receptor activity GO:0030594 9.62 HTR1A HTR1B HTR2A HTR2C
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.61 DRD2 DRD3 DRD4
5 dopamine neurotransmitter receptor activity GO:0004952 9.58 DRD2 DRD3 DRD4
6 neurotransmitter:sodium symporter activity GO:0005328 9.57 SLC6A3 SLC6A4
7 G-protein coupled serotonin receptor activity GO:0004993 9.56 HTR1A HTR1B HTR2A HTR2C
8 monoamine transmembrane transporter activity GO:0008504 9.55 SLC6A3 SLC6A4
9 primary amine oxidase activity GO:0008131 9.54 MAOA MAOB
10 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.52 TPH1 TPH2
11 dopamine:sodium symporter activity GO:0005330 9.51 SLC6A3 SLC6A4
12 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.49 HTR2A HTR2C
13 tryptophan 5-monooxygenase activity GO:0004510 9.48 TPH1 TPH2
14 dopamine binding GO:0035240 9.46 DRD2 DRD3 DRD4 SLC6A3
15 serotonin binding GO:0051378 9.26 HTR1A HTR1B HTR2A HTR2C
16 drug binding GO:0008144 9.17 DRD2 DRD3 DRD4 HTR1B HTR2A HTR2C
17 G-protein coupled receptor activity GO:0004930 10 DRD2 DRD3 DRD4 HTR1A HTR1B HTR2A

Sources for Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....